CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression and restore healthy protein levels [1][3] - The company is working on disease-modifying treatments for a wide range of rare and prevalent genetic diseases, where increasing healthy protein levels may provide significant therapeutic benefits [3] Upcoming Event - Josh Mandel-Brehm, President & CEO of CAMP4, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 3:45 p.m. PST [1] - The event will be available for live webcast on CAMP4's investor relations page, with a replay archived for 30 days post-conference [2] Technology and Approach - CAMP4's proprietary RAP Platform™ enables the mapping of regRNAs and the generation of therapeutic candidates aimed at targeting regRNAs associated with genes involved in haploinsufficient and recessive partial loss-of-function disorders [3] - There are over 1,200 disorders where a modest increase in protein expression could have clinically meaningful effects [3]